Our approach
Not a discovery gamble. A validated target, de-risked.
Most oncology assets fail on the target, not the chemistry — most “cancer targets” are merely over-expressed, so they still bind healthy tissue and drive toxicity. We start from a target that is genuinely cancer-exclusive.
01 / TARGET
A cancer-exclusive antigen
A surface target present on cancer cells and absent from the surface of healthy ones — the basis for a wide therapeutic window. Validated on patient biopsies, cell lines and animal models.
02 / DRUG
A lead ADC against it
We built an antibody–drug conjugate that binds the target on tumor cells and delivers a cytotoxic payload precisely — a familiar, high-value modality with clear regulatory and commercial precedent.
03 / PLATFORM
An engine to find more
The discovery platform that identified our lead target is repeatable across cancer types — turning a single validated asset into a pipeline, and Oncotope into more than one shot on goal.
Pipeline
One validated target. Four modalities.
Every program is built against the same cancer-exclusive target — multiple shots on goal from a single, de-risked foundation. Specific target identity, payloads and preclinical data are shared with qualified investors under NDA.
Asset
ONC-001-ADC
Lead program
Antibody–drug conjugate
Breast & prostate · lead value driver
ONC-001-RC
Radioconjugate theranostic
Imaging + therapy from one target
ONC-001-DX
Companion diagnostic
Patient selection · earliest to revenue
The Oncotope Platform
A repeatable discovery engine.
The platform behind our lead asset finds cancer-exclusive surface targets across cancer types — turning one validated target into a pipeline. The methodology is proprietary.
Cancer-exclusive by design
The engine surfaces antigens present on cancer cells and absent from healthy tissue — the property that drives a wide therapeutic window and low off-target risk.
Antibody-matched from the start
Each target the platform identifies arrives with a validated, cancer-specific antibody already matched to it — ready to build into ADCs, radioconjugates and diagnostics.
Repeatable across cancers
The same approach applies to new cancer types, generating fresh targets and programs — the basis for platform value beyond the lead asset.
1
Validated cancer-exclusive target
3
Modalities from one target
2
Lead indications: breast & prostate
∞
Platform, repeatable across cancers
The opportunity
A validated asset today. A platform tomorrow.
We’re advancing our lead ADC toward IND and expanding the pipeline the platform enables. Our full deck, program data and terms are shared with qualified investors under NDA — we’d welcome a conversation.